Raffaele Marco, Carota Giuseppe, Sferrazzo Giuseppe, Licari Maria, Barbagallo Ignazio, Sorrenti Valeria, Signorelli Salvatore S, Vanella Luca
Department of Drug Science, Biochemistry Section, University of Catania, 95125 Catania, Italy.
Department of Clinical and Experimental Medicine, University of Catania, 95125 Catania, Italy.
Antioxidants (Basel). 2019 Aug 5;8(8):277. doi: 10.3390/antiox8080277.
The progression of non-alcoholic fatty liver disease (NAFLD) and the development of hepatic fibrosis is caused by changes in redox balance, leading to an increase of reactive oxygen species (ROS) levels. NAFLD patients are at risk of progressing to non-alcoholic steatohepatitis (NASH), associated to cardiovascular diseases (CVD), coronary heart disease and stroke. Heme Oxygenase-1 (HO-1) is a potent endogenous antioxidant gene that plays a key role in decreasing oxidative stress. The present work was directed to determine whether use of an inhibitor of HO-1 activity affects lipid metabolism and fibrosis process in hepatic cells. Oil Red assay and mRNA analysis were used to evaluate the triglycerides content and the lipid metabolism pathway in HepG2 cells. ROS measurement, RT-PCR and Soluble collagen assay were used to assess the intracellular oxidant, the fibrosis pathway and the soluble collagen in LX2 cells. The activity of HO-1 was inhibited using Tin Mesoporphyrin IX (SnMP). Our study demonstrates that a non-functional HO system results in an increased lipid storage and collagen release in hepatocytes. Consequently, an increase of HO-1 levels may provide a therapeutic approach to address the metabolic alterations associated with NAFLD and its progression to NASH.
非酒精性脂肪性肝病(NAFLD)的进展和肝纤维化的发展是由氧化还原平衡的变化引起的,导致活性氧(ROS)水平升高。NAFLD患者有进展为非酒精性脂肪性肝炎(NASH)的风险,这与心血管疾病(CVD)、冠心病和中风有关。血红素加氧酶-1(HO-1)是一种强大的内源性抗氧化基因,在降低氧化应激方面起关键作用。本研究旨在确定使用HO-1活性抑制剂是否会影响肝细胞中的脂质代谢和纤维化过程。采用油红染色法和mRNA分析来评估HepG2细胞中的甘油三酯含量和脂质代谢途径。采用ROS检测、RT-PCR和可溶性胶原蛋白检测来评估LX2细胞中的细胞内氧化剂、纤维化途径和可溶性胶原蛋白。使用中卟啉锡(SnMP)抑制HO-1的活性。我们的研究表明,无功能的HO系统会导致肝细胞中脂质储存增加和胶原蛋白释放增加。因此,提高HO-1水平可能为解决与NAFLD及其进展为NASH相关的代谢改变提供一种治疗方法。